Reuters: Health
Chinese regulators have approved Novartis' Mayzent to treat relapsing multiple sclerosis in adults, the Swiss drug maker said in a statement on Saturday.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
Popular Posts
|
No comments:
Post a Comment